blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3802802

EP3802802 - CELL THERAPY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  12.03.2021
Database last updated on 06.11.2024
FormerThe international publication has been made
Status updated on  07.12.2019
Most recent event   Tooltip13.04.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Tune Therapeutics, Inc.
1616 Eastlake Avenue E, Suite 208
Seattle, WA 98102 / US
[2022/46]
Former [2021/15]For all designated states
M2X2 Therapeutics, Inc.
555 Bryant Street Suite 259
Palo Alto CA 94301 / US
Inventor(s)01 / MCHUGH, Daniel
555 Bryant Street, Suite 259
Palo Alto, California 94301 / US
 [2021/15]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2021/15]HGF
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date19812135.229.05.2019
[2021/15]
WO2019US34421
Priority number, dateUS201862678043P30.05.2018         Original published format: US 201862678043 P
US201862681307P06.06.2018         Original published format: US 201862681307 P
[2021/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019232069
Date:05.12.2019
Language:EN
[2019/49]
Type: A1 Application with search report 
No.:EP3802802
Date:14.04.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 05.12.2019 takes the place of the publication of the European patent application.
[2021/15]
Search report(s)International search report - published on:US05.12.2019
(Supplementary) European search report - dispatched on:EP16.03.2023
ClassificationIPC:C12N15/113, C12N9/10, C12N9/22, A61K35/15, A61K35/17
[2023/16]
CPC:
C12Y301/00 (EP); A61K35/17 (US); A61K39/4611 (EP);
A61K39/4631 (EP); A61K39/4644 (EP); C12N15/11 (US);
C12N15/113 (EP); C12N15/907 (EP); C12N9/0071 (US);
C12N9/22 (EP,US); A61K38/00 (EP); A61K48/00 (EP);
C12N2310/20 (EP,US) (-)
Former IPC [2021/15]C12N9/10, C12N9/22
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/15]
TitleGerman:ZELLTHERAPIE[2021/15]
English:CELL THERAPY[2021/15]
French:THÉRAPIE CELLULAIRE[2021/15]
Entry into regional phase21.12.2020National basic fee paid 
21.12.2020Search fee paid 
21.12.2020Designation fee(s) paid 
21.12.2020Examination fee paid 
Examination procedure21.12.2020Examination requested  [2021/15]
16.10.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
27.05.2021Renewal fee patent year 03
16.03.2022Renewal fee patent year 04
12.04.2023Renewal fee patent year 05
12.04.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2016177892  (UNIVERSITÉ DE LAUSANNE [CH]) [A] 1-13 * examples 1-8; claims 1-13 *;
 [A]WO2016183345  (SEATTLE CHILDREN' S HOSPITAL (DBA SEATTLE CHILDREN 'S RES INSTITUTE) [US]) [A] 1-13 * example 20 *;
 [A]WO2017079622  (UNIV EMORY [US], et al) [A] 1-13 * page 23 - page 29; claims 1-10 *;
 [YA]WO2017165412  (DANA FARBER CANCER INST INC [US], et al) [Y] 1 * examples 2-6; claims 1-10, 28-36, 40-52,62-69 * [A] 2-13;
 [XY]WO2018031762  (UNIV DUKE [US]) [X] 2,3,5-10,12,13 * paragraphs [0037] , [0 42] , [0 43] , [0 65] , [ 129] , [ 140] - [0149]; claims 1,26, 33-42 * [Y] 1;
 [X]WO2018035495  (WHITEHEAD INST BIOMEDICAL RES [US]) [X] 2-8,10-13 * paragraphs [0061] , [0 70] , [ 123]; claims 1-19,25,26,44,45 *;
 [A]  - FUQIN ZHANG ET AL, "Epigenetic Manipulation Restores Functions of Defective CD8+ T Cells From Chronic Viral Infection", MOLECULAR THERAPY, US, (20140701), vol. 22, no. 9, doi:10.1038/mt.2014.91, ISSN 1525-0016, pages 1698 - 1706, XP055467808 [A] 1-13 * figures 4,5 *

DOI:   http://dx.doi.org/10.1038/mt.2014.91
 [A]  - YI LANG ET AL, "CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, (20160915), vol. 1866, no. 2, doi:10.1016/J.BBCAN.2016.09.002, ISSN 0304-419X, pages 197 - 207, XP029826231 [A] 1-13 * page 201; figure 3 *

DOI:   http://dx.doi.org/10.1016/j.bbcan.2016.09.002
 [A]  - PULECIO JULIAN ET AL, "CRISPR/Cas9-Based Engineering of the Epigenome", CELL STEM CELL, (20171005), vol. 21, no. 4, doi:10.1016/J.STEM.2017.09.006, ISSN 1934-5909, pages 431 - 447, XP085208267 [A] 1-13 * figures 1,2 *

DOI:   http://dx.doi.org/10.1016/j.stem.2017.09.006
 [A]  - WU JIAZHU ET AL, "Unlocking the epigenetic code of T cell exhaustion", TRANSLATIONAL CANCER RESEARCH, (20170331), vol. 6, no. S2, doi:10.21037/tcr.2017.03.02, ISSN 2218-676X, pages S384 - S387, XP055848259 [A] 1-13 * page S386, column r *

DOI:   http://dx.doi.org/10.21037/tcr.2017.03.02
 [A]  - BENGSCH BERTRAM ET AL, "Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells", IMMUNITY, CELL PRESS, AMSTERDAM, NL, (20180515), vol. 48, no. 5, doi:10.1016/J.IMMUNI.2018.04.026, ISSN 1074-7613, page 1029, XP085397208 [A] 1-13 * figure 2 *

DOI:   http://dx.doi.org/10.1016/j.immuni.2018.04.026
 [A]  - SEN D. R. ET AL, "The epigenetic landscape of T cell exhaustion", SCIENCE, US, (20161027), vol. 354, no. 6316, doi:10.1126/science.aae0491, ISSN 0036-8075, pages 1165 - 1169, XP055848381 [A] 1-13 * figures 1,4 *

DOI:   http://dx.doi.org/10.1126/science.aae0491
International search[A]WO2017049266  (UNIV CALIFORNIA [US]) [A] 1-152* entire document *;
 [A]WO2017070632  (HARVARD COLLEGE [US]) [A] 1-152 * entire document *;
 [Y]US2017327806  (JOUNG J KEITH [US], et al) [Y] 4-6, 32-50, 54-56, 80-96, 100-102, 131-152 * entire document *;
 [XY]WO2018035388  (BROAD INST INC [US], et al) [X] 1-3, 7-31, 51-53, 57-79, 97-99, 103-130 * entire document * [Y] 4-6, 32-50, 54-56, 80-96, 100-102, 131-152;
 [A]  - HENNING et al., "Epigenetic control of CD 8+ T cell differentiation", Nature Reviews Immunology, (20180130), vol. 18, no. 5, pages 340 - 356, XP055660663 [A] 1-152 * . entire document *

DOI:   http://dx.doi.org/10.1038/nri.2017.146
 [A]  - PUCCINI et al., "Colorectal cancer: epigenetic alterations and their clinical implications", Biochimica et Biophysica Acta, (20170920), vol. 1868, no. 2, pages 439 - 448, XP085255166 [A] 1-152 * . entire document *

DOI:   http://dx.doi.org/10.1016/j.bbcan.2017.09.003
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.